Alicia Uijl presents the results of an analysis that identified five phenotypic clusters in HFpEF with differences in medication profile, morbidity and mortality.
Microvascular disease (MVD) was associated with the development of HF in adults with T2DM, independently of traditional risk factors including CAD.
Besides current recommendations of GLP-1RA therapy for patients with T2DM and comorbidities to reduce CV events, Frederik Persson discusses future possibilities for use of GLP-1RA. With question to test your knowledge.
This study showed that prescription rates of evidence-based medical therapies are suboptimal in patients with comorbid HFrEF and CKD, even at eGFR levels where therapies are not contraindicated by kidney dysfunction.
Prof. Rossing talks about setting treatment goals for patients with T2DM and CKD. These treatment goals are not limited to risk factor control but are also focused on organ protection.
This analysis of the PIVOTAL trial showed that treatment with high-dose IV iron administered proactively, compared to low-dose IV iron administered reactively, decreased the occurrence of first and recurrent HF events in patients receiving hemodialysis.
Jackie Bosch presents the results of the HOPE-3 study that show that CV benefits of statin treatment continued for at least three more years after stopping medication in individuals at intermediate risk for CV events.
A subanalysis of ETNA-AF-Europe showed that AF patients using edoxaban who had lower or higher weight than the reference group had similar low rates of stroke and bleeding.
EMPEROR-Preserved met its primary endpoint and showed a significant risk reduction with empagliflozin for the composite endpoint of time to first event of CV death or HF hospitalization compared to placebo in adults with HFpEF, with or without T2DM.
ESC HF 2021 The treatment effect of beta-blockers on all-cause mortality in HFpEF patients was heterogenous across clusters of HFpEF, with a significant reduction in the young cluster and the AF-hypertension cluster.
ESC HF 2021 Dapagliflozin improved HF symptoms (measured by KCCQ-TSS) in HFrEF compared to placebo, but did not improve physical limitations (measured by KCCQ-PLS) or 6 minute walk distance. No significant improvements with dapagliflozin in any of these outcomes were seen in HFpEF.
Administration of NTLA-2001 for TTR editing and knockout in patients with hereditary ATTR amyloidosis resulted in large reductions of serum TTR protein levels at day 28.